Sorry, this entry is only available in Italiano. Dopo i minerali, PharmaNutra applica con successo la Tecnologia Sucrosomiale® anche alle […]
The Group obtains approval of the Cetilar® patent in the USA and new prospects unfold for SiderAL® in India thanks to […]
The new patent, valid until 2037, opens PharmaNutra up to the possibility of developing specific products for the cardiovascular field, […]
After Europe, the intellectual property rights of the patent expiring in 2033 are now acknowledged in the United States. A […]
